- Exchange: OTC US
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Diamyd Medical AB
+ Add to WatchlistDMYDY:US
2.1340 USD 0.0660 3.00%As of 20:10:00 ET on 05/21/2013.
Snapshot for Diamyd Medical AB (DMYDY)
| Open: | 2.1340 | Day's Range: | 2.1340 - 2.1340 | Volume: | 100 |
|---|---|---|---|---|---|
| Previous Close: | 2.2000 | 52wk Range: | 0.9500 - 2.2500 | 1-Yr Rtn: | +38.57% |
Key Statistics for DMYDY
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(-) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (ttm) | - |
| Est. EPS | - |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 60.05 |
| Shares Outstanding (M) | 28.14 |
| 30 Day Average Volume | 704 |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | - |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend (USD) | 1.2546 |
| Last Dividend | 11/04/2009 |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 07/03/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for DMYDY
Company Profile & Key Executives for DMYDY
Mertiva AB develops and markets products for the diagnosis, prevention, and treatment of diabetes. The Company also develops, produces and sells in vitro diagnostic tests for diabetes.Mertiva AB sells its products to the research market worldwide.
| Anders Essen-MoellerChairman | Andreas BergstenPresident/CEO |
| Anna StyrudChief Financial Officer | Darren WolfeCEO:USA |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
DMYDY News
-
Industry News
Advertisement
- 1
- 2
- 3
- 4
- 5
Advertisement
Sponsored Links
Advertisements
Rate this Page